Numinus announces a product development agreement with Optimi Health Corp.
Exploring the companies and themes that make up this emerging and exciting new sector
CYBIN Provides Update on Patent Filings & Development of Therapeutics Program
Cybin Corp updates investors on its IP development
North America Psychedelic Drugs Market Could Exceed $6.8 Billion By 2027
PALM BEACH, Fla., Jan. 6, 2021 /PRNewswire/ -- In the few places where cannabis is legal, it can be incredibly lucrative. In 2019, the nascent worldwide cannabis sector pumped out approximately $15 billion in sales.
Minerco Inc The Magic Mushroom Company Signs LOI with Jamaican Firm Lazurus Holistic to Grow, Process and Extract Psilocybin and Cannabis for Export to Canada and Europe
Oakland, California--(Newsfile Corp. - January 4, 2021) - OTC:MINE signs a Joint Venture letter of intent with Lazurus Holistic to serve as psilocybin experts to grow and develop a unique strain of mushrooms specific to Jamaica.
Four Top Psychedelic Stock Picks for 2021
ATLANTA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- 2020 was a banner year for investors in psychedelic companies as investors in Mind Medicine (MindMed) Inc. (OTCQB: MMEDF), 20/20 Global, Inc. (OTC: TWGL), Compass Pathways (NASDAQ: CMPS), and Numinus Wellness Inc. (OTC: LKYSF) saw their money triple and even quadruple.
Might a safer version of a psychedelic help treat depression?
Research in animals suggests that the new compound is neither toxic nor hallucinogenic and that it may help treat a range of psychiatric disorders, including depression and addiction, and possibly anxiety and post-traumatic stress disorder (PTSD).
Best Music Playlists For Psychedelic Therapy Are Explored In New Johns Hopkins Study
Psychedelic therapy sessions often incorporate music—and typically that music is of the classical genre.
Entheon Biomedical Announces Investment and Business Arrangement with Heading Health LLC
Vancouver, British Columbia--(Newsfile Corp. - January 4, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is announcing a business arrangement with, and a strategic investment in, Heading Health, LLC ("Heading Health"), a psychiatric clinic platform focused on the administration of psychedelic-assisted therapy to treat mental health disorders.
Psilocybin Could be Key to Helping Millions of People with Eating Disorders
With clinical trials supporting psychedelics, like psilocybin mushrooms for the treatment of obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression and anxiety, it’s only a matter of time before big pharmaceutical companies begin to invest heavily, and incorporate psychedelics into their own drug pipelines.
Release: Mind Cure (CSE: MCUR | OTC: MCURF) Announces Retail Roll Out of Nootropics Lineup Across North America with Body Energy Club
Mind Cure's nootropic products are set to launch across 17 locations within North America starting Feb, 2021.
Legal Psychedelic Therapy Comes to Alberta With Ground-Breaking Health Canada Decision
Health Canada issues its first Section 56 Exemption for psilocybin use to an Alberta resident.
Mike Tyson scoffs four grams of magic mushrooms after smoking joint on Logan Paul podcast as he opens up on drug use
MIKE TYSON caused a stir after scoffing four grams of magic mushrooms on Logan Paul’s podcast.